Advertisement
Screener

OMNIAB, INC. (OABI) Graph

OABI Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2021-03-31: Net income -$7.79K.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OABI revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Royalty$266.00KService$2.47MLicense AndMilestone Revenue$9.52MX Ploration Revenue$1.16MRevenue$13.42MOperating expenses$20.05MOperating income-$6.64MOther income, net-$9.00KResearch & development$9.59MPre-tax income-$6.21MIncome tax-$353.00KNet income-$5.86M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OABI revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$13.42MRevenue$13.42MOperating expenses$20.05MOperating income-$6.64MOther income, net-$9.00KResearch & development$9.59MPre-tax income-$6.21MIncome tax-$353.00KNet income-$5.86M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 2 month

Period endNet income
2021-03-31-$7.79K

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$13.41M$9.59M$20.05M-$353.00K-$5.86M
2026-03-31$14.43M$9.64M$22.26M$442.00K-$7.71M
2025-12-31$8.38M*$13.91M*$24.14M*-$367.00K*-$14.18M*
2025-09-30$2.24M$10.38M$20.38M-$1.16M-$16.52M
2025-06-30$3.90M$10.86M$20.12M$119.00K-$15.88M
2025-03-31$4.15M$12.60M$23.00M-$106.00K-$18.20M
2024-09-30$4.17M$13.32M$23.94M-$2.71M-$16.37M
2024-06-30$7.61M$13.94M$23.92M-$1.90M-$13.63M
2024-03-31$3.80M$14.55M$26.35M-$2.62M-$18.96M
2023-09-30$5.48M$13.87M$25.79M-$3.30M-$15.74M
2023-06-30$6.95M$14.13M$26.39M-$3.44M-$14.73M
2023-03-31$16.92M$13.76M$25.37M-$1.03M-$6.10M
2022-09-30$6.91M$13.19M$21.82M-$2.31M-$12.60M
2022-06-30$7.20M$11.48M$19.77M-$2.29M-$10.28M
2022-03-31$9.62M$10.77M$17.85M-$1.94M-$6.28M
2021-09-30(m)(m)(m)(m)-$170.58K
2021-06-30(m)(m)(m)(m)-$2.19K

Revenue and expense 5 month

Period endNet income
2021-06-30-$9.97K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$27.84M$19.23M$42.31M$89.00K-$13.57M
2025-06-30$8.05M$23.47M$43.11M$13.00K-$34.08M
2024-06-30$11.41M$28.49M$50.27M-$4.51M-$32.59M
2023-06-30$23.86M$27.89M$51.76M-$4.46M-$20.83M
2022-06-30$16.82M$22.26M$37.61M-$4.23M-$16.56M

Revenue and expense 8 month

Period endNet income
2021-09-30-$180.55K

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$10.29M$33.84M$63.49M-$1.15M-$50.60M
2024-09-30$15.59M$41.80M$74.21M-$7.22M-$48.97M
2023-09-30$29.34M$41.76M$77.56M-$7.77M-$36.57M
2022-09-30$23.73M$35.45M$59.43M-$6.54M-$29.15M

Revenue and expense 11 month

Period endNet income
2021-12-31-$516.44K

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$18.67M$47.75M$87.64M-$1.51M-$64.78M
2024-12-31$26.39M$55.11M$100.89M-$9.38M-$62.03M
2023-12-31$34.16M$56.52M$103.58M-$13.74M-$50.62M
2022-12-31$59.08M$48.36M$85.72M-$3.73M-$22.33M
2021-12-31$34.75M$39.23M$70.36M-$7.31M-$27.04M

Similar stocks

Stock NameCountryMarket CapPE Ratio
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14